S. Agrawal

Osimertinib-Associated Cardiotoxicity in EGFR-Mutant Non-Small Cell Lung Cancer: Mechanisms, Phenotypes, and Surveillance.

Osimertinib, a third-generation EGFR-TKI, is now the standard first-line treatment for EGFR-mutant non-small cell lung cancer and is increasingly given in the adjuvant setting for up to 3 years and in combination with chemotherapy. As exposure has lengthened and shifted toward curative-intent settings, its cardiac effe...